Trial
OCEAN(a)-DOSE
Status Completed, published NEJM 2022 (extension JACC 2024)
281 patients with ASCVD and Lp(a) above 150 nmol/L (median 260) received olpasiran 10, 75 or 225 mg every 12 weeks, 225 mg every 24 weeks or placebo: placebo-adjusted Lp(a) reductions at week 36 of 70.5, 97.4, 101.1 and 100.5 percent, injection-site reactions the main adverse event. Off treatment, Lp(a) was still 40 to 50 percent below baseline nearly a year after the last dose.
Selected 75 mg every 12 weeks for OCEAN(a)-Outcomes. Substudies: OxPL-apoB down about 90 percent without change in hs-CRP or IL-6 (JAMA Cardiol 2025); reductions consistent across baseline Lp(a) strata (EHJ 2025).
Page updated 17 August 2026.